Register Today to Attend the Virtual NASH Externally Led Patient Focused Drug Development (PFDD) Meeting on November 4, 2021!
Global Liver Institute (GLI) is excited to work with the liver advocacy community, including the member organizations within GLI’s Liver Action Network (LAN), to lead the first nonalcoholic steatohepatitis (NASH) Externally Led Patient Focused Drug Development Meeting (EL PFDD) to be held virtually on November 4, 2021. A PFDD meeting of this magnitude will allow the U.S. Food and Drug Administration (FDA) and other stakeholders across the medical field to obtain a wide range of patients' and caregivers' input on NASH, including their perspectives on their condition, its impact on daily life, and the urgency around developing therapies.
This EL PFDD meeting will also provide an opportunity to present critical data gathered from GLI's NASH patient and caregiver survey, along with testimony from a diverse group of patients and caregivers impacted by NASH. The combination of surfaced data from the survey, and virtual testimonies will provide clarity on the priorities and preferences for addressing NASH by individuals who have NASH themselves, and caregivers of people with NASH.
The EL PFDD meeting is a critical first step in providing the entire health community with a deeper understanding of NASH. We hope to see you there!
Disclaimer: By completing this form you will be opted-in to receive email from the Global Liver Institute (GLI). You may unsubscribe at any time by either clicking on the appropriate link in the email or contacting us at advocacy@globalliver.org.